Abstract |
Chronic inflammatory demyelinating polyradiculoneuropathy ( CIDP) and its variants can be challenging to diagnose and treat. A combination of clinical, electrophysiological and laboratory features is often required to reach a diagnosis. New data are emerging about potential biomarkers and factors that may indicate treatment needs in individual patients. High-quality evidence exists for the efficacy of intravenous immunoglobulin ( IVIG) in the treatment of CIDP, including quality of life (QoL) benefits. Besides pharmacological treatment, psychological factors must also be addressed to improve patients' QoL. Home-based IVIG infusion therapy is currently a well-established approach in some countries. A 6-month pilot study conducted in Ontario, Canada, provided proof of safety and patient acceptance of home-based IVIG therapy, although some logistical issues emerged.
|
Authors | Yusuf A Rajabally, Patricia H Blomkwist-Markens, Hans D Katzberg |
Journal | Neurodegenerative disease management
(Neurodegener Dis Manag)
Vol. 5
Issue 3
Pg. 257-68
( 2015)
ISSN: 1758-2032 [Electronic] England |
PMID | 26107324
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't, Review)
|
Chemical References |
- Biomarkers
- Immunoglobulins
|
Topics |
- Biomarkers
(metabolism)
- Humans
- Immunoglobulins
(administration & dosage)
- Polyradiculoneuropathy, Chronic Inflammatory Demyelinating
(diagnosis, metabolism, therapy)
- Quality of Life
- Voice
|